Intervention1: Two Intramuscular injections with either of the three formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcg (adjuvanted)] of H1N1 vaccines: 0.5 ml of either of the thre

A Phase II/III clinical Study to Evaluate the Immunogenicity and Safety of Three Formulations of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 3-9 years of Age.

A phase II/III clinical study to evaluate the immunogenicity and safety of three formulations of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults.